The high frequency of intrinsic resistance to TNF-related apoptosisinducing ligand (TRAIL) in tumor cell lines has necessitated the development of strategies to sensitize tumors to TRAIL-induced apoptosis. We previously showed that elevated pressure applied as a mechanical stressor enhanced TRAIL-mediated apoptosis in human lung carcinoma cells in vitro and in vivo. This study focused on the effect of elevated pressure on the sensitization of TRAIL-resistant cells and the underlying mechanism. We observed elevated pressure-induced sensitization to TRAIL-mediated apoptosis in Hep3B cells, accompanied by the activation of several caspases and the mitochondrial signaling pathway. Interestingly, the enhanced apoptosis induced by elevated pressure was correlated with suppression of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) phosphorylation and CREB without any change to other MAPKs. Phosphorylation of Bcl-2-associated death promoter (BAD) also decreased, leading to inhibition of the mitochondrial pathway. To confirm whether the activation of pERK1/2 plays a key role in the TRAIL-sensitizing effect of elevated pressure, Hep3B cells were pre-treated with the ERK1/2-Vol. 20. No. 4. 2015 CELL. MOL. BIOL. LETT. 536 specific inhibitor PD98059 instead of elevated pressure. Co-treatment with PD98059 and TRAIL augmented TRAIL-induced apoptosis and decreased BAD phosphorylation. The inhibition of ERK1/2 activation by elevated pressure and PD98059 also reduced BH3 interacting-domain death agonist (BID), thereby amplifying apoptotic stress at the mitochondrial level. Our results suggest that elevated pressure enhances TRAIL-induced apoptosis of Hep3B cells via specific suppression of ERK1/2 activation among MAPKs.
INTRODUCTION
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor superfamily, preferentially induces apoptosis of tumor cells with little or no toxicity towards most normal cells [1, 2] . This selective toxicity for cancer cells makes TRAIL an excellent candidate for anticancer therapy [3] . Moreover, phase II clinical studies have shown that an agonistic antibody specific for TRAIL receptors is safe and well tolerated in patients with advanced colorectal cancer and non-small cell lung cancer [4, 5] . Despite the powerful activity of TRAIL towards most types of cancer cell, the resistance of tumor cells to TRAIL-induced apoptosis is a major obstacle to the development of TRAIL-based anticancer therapies [6] . Therefore, several approaches have been employed to increase the sensitivity of tumor cells to TRAIL, including combinations of drugs with different mechanisms of action [7] . Although combinatorial therapy can elicit enhanced TRAIL-mediated apoptosis in a variety of tumor cell lines, it might also sensitize normal cells. We recently showed that applying elevated pressure as a mechanical stimulus enhances TRAIL-mediated apoptosis through upregulation of death receptor 5 (DR5) and activation of caspase-8 in various cancer cells. That was the first demonstration of apoptosis potentiation in cancer cells by TRAIL and elevated pressure [8, 9] . In addition, toxicity was not seen in normal fibroblasts exposed to a combination of elevated pressure and drugs that can induce apoptosis in cancer cells [10] . However, despite these advances, little is known about the mechanism by which elevated pressure increases TRAIL-mediated cell death. Mechanical forces activate many types of signal transduction cascade in cancer progression [11] . A widely investigated signal transduction pathway is the mitogen-activated protein kinase (MAPK) pathway, which converts extracellular mechanical signals into biological signals and is essential for cell proliferation, migration and apoptosis [12, 13] . In particular, the MAPK/ERK1/2 pathway plays a role in cell survival by preventing the induction of apoptosis [14] [15] [16] [17] . Thus, inhibition of the MAPK/ERK1/2 pathway increases the sensitivity of tumor cells to TRAIL-induced apoptosis. However, there are no reports on role of ERK1/2 in TRAIL-mediated apoptosis induced by elevated pressure.
In this study, we investigated the effect of elevated pressure on cell death in TRAIL-resistant cells. Our results indicate that the ERK1/2 pathway might trigger TRAIL-induced apoptosis in cells sensitized with mechanical pressure. Reduction of phosphorylated BAD and cAMP response element-binding protein (CREB) through co-treatment of cells with TRAIL and elevated pressure was observed in TRAIL-induced apoptosis through amplification of the mitochondrial pathway.
MATERIALS AND METHODS

Reagents
Recombinant human TRAIL and zVAD-FMK were purchased from Peprotech. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) powder and DMSO were purchased from Sigma. Antibodies for caspases-3, -8, -9, Bid, Bax, Bcl2, XIAP, phosphorylated ERK, ERK, phosphorylated CREB, CREB, phosphorylated Bad(s112) and Bad were purchased from Cell Signaling. Antibodies for DR4 and DR5 were from Abcam. Anti-polyclonal antibodies for GAPDH were from Santa Cruz Biotechnology. Secondary antibodies were from GE Healthcare Bio-Sciences AB.
Cell line and culture conditions
Hep3B (human hepatocellular carcinoma) cells from the American Type Culture Collection were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics in an atmosphere of 95% air and 5% CO 2 . Cultured cells were treated with TRAIL and then exposed to normoxia (95% air, 5% CO 2 , pCO 2 = 38 mm Hg, pO 2 = 146.566-147.288 mm Hg) as a control condition and to elevated pressure (with mild oxygenation in the air at 2 ATA, 5% CO 2 , pCO 2 = 38.228 mmHg, pO 2 = 305.9-306.66 mmHg) for various periods.
In vitro cytotoxicity and apoptosis assays Cell viability was measured using the MTT assay. The formazan reaction product was quantified spectrophotometrically at 570 nm using a VERSAmax ELISA reader (Molecular Devices). Apoptosis was induced by the addition of 50 ng/ml TRAIL (Peprotech) and elevated pressure. After 48 h, cells were harvested and stained using annexin V Alexa Fluor 488 and propidium iodide, as described for the Tali Apoptosis Kit (Invitrogen). Stained cells were analyzed by a Tali Image-Based Cytometer (Invitrogen).
Western blot analysis
Cell lysates (20 μg) were separated in SDS-PAGE gels and transferred to PVDF membranes (Millipore). The membranes were probed with antibodies against the proteins of interest, washed with 0.1% Tween 20 in PBS, and incubated with a peroxidase-conjugated secondary antibody. The immunoreactivity was detected using an ECL kit (Amersham Biosciences) and quantitative data were obtained using molecular imaging software (Kodak).
Phospho-MAPK array
The relative levels of phosphorylated MAPKs and other serine and threonine kinases were detected using phospho-MAPK array kits (R&D systems, Inc.) according to the manufacturer's instructions. Cell lysates were diluted and incubated with the human phospho-MAPK array. After binding of the phosphorylated and unphosphorylated kinases, the unbound material was washed away. A cocktail of phospho-site-specific biotinylated antibodies was used to detect phosphorylated kinases via streptavidin-HRP and chemiluminescence.
Mitochondrial outer membrane permeabilization (MOMP) assay
The mitochondrial membrane potential of cells was measured using the Mitoprobe JC-Assay Kit (Molecular Probes) with some modifications. Briefly, harvested cells were incubated with 1 μM JC-1 at 37ºC in a humidified incubator with 5% CO 2 for 10-30 min. After two washes, the cells were resuspended in PBS and immediately analyzed using a Tali Image-Based Cytometer (Invitrogen).
Statistical analysis
Data are expressed as means ± SE at least for three independent experiments. Student's t-test and two-way ANOVA were used for statistical analysis.
RESULTS
Elevated pressure triggers TRAIL-induced apoptosis through caspase activation
We previously identified elevated pressure as a TRAIL sensitizer in various cancer cell lines. To confirm the sensitizing effect of elevated pressure, Hep3B cells were treated with TRAIL with or without elevated pressure, and cell viability and apoptosis were subsequently analyzed. Elevated pressure reduced cell survival when combined with TRAIL treatment (Fig. 1A) . Cell death was markedly increased in cells treated with both elevated pressure and TRAIL, but only slightly increased in cells treated with elevated pressure or TRAIL alone (Fig. 1B) . We next investigated whether the increase in cell death induced by combined elevated pressure and TRAIL treatment depended on caspase activation. Co-treatment with elevated pressure and TRAIL reduced the expression of caspase-8, -9 and -3. By contrast, little or no change in caspase expression levels was observed in cells treated with elevated pressure or TRAIL alone (Fig. 1C) . To further investigate the involvement of caspases in enhanced apoptosis, cells co-treated with elevated pressure and TRAIL were pre-treated with inhibitors for general caspase, caspase-8 and caspase-9: 20 μM of zVAD-fmk, zIETD-fmk and z-IEHD-fmk, respectively. Pre-incubation with caspase inhibitors prevented the induction of apoptosis by elevated pressure and TRAIL co-treatment (Fig. 1D) . These results suggest that elevated pressure stimulates TRAIL-induced apoptosis through caspase activation. Fig. 1 . Elevated pressure enhances TRAIL-induced apoptosis through the activation of caspases. Hep3B cells were treated with 50 ng/ml tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and/or elevated pressure (EP) for 48 h. A -Cell viability was measured using the MTT assay. B -Cell death was measured via annexin V and propidium iodide (PI) staining and is presented as the percentage of annexin V-positive cells. Among the annexin V-positive cell population, only 0-2% showed annexin V-and PI-double positive cells, concluding that apoptosis is the most common form of cell death. **p < 0.001 (significant difference). C -Protein lysates were probed for caspase-8, -9 and -3, and GAPDH using western blot analysis. D -Hep3B cells were pre-treated for 1 h with irreversible and cell-permeable inhibitors of general caspase, caspase-8 or caspase-9: 20 μM of Z-VAD-fmk, Z-IETD-fmk or Z-LEHD-fmk, respectively. Treatment with TRAIL and/or elevated pressure followed. Cell death was measured as described in A. *p < 0.05 and **p < 0.001 (significant difference). The histogram values were expressed as the means ± standard deviation (SD) from three to five independent experiments. Representative blots from three independent experiments are shown; GAPDH was used as the loading control.
Co-treatment with elevated pressure and TRAIL amplifies mitochondrial signaling To investigate the mechanism responsible for elevated pressure-mediated sensitization to TRAIL-induced apoptosis, we analyzed the effects of elevated pressure, TRAIL, and their combination on key proteins of the TRAIL apoptosis pathway. The expression levels of TRAIL receptors such as DR4 and DR5 were not affected by TRAIL treatment alone or in combination with elevated pressure. Fig. 2 . Co-treatment with elevated pressure and TRAIL activates apoptotic signaling. A and B -Hep3B cells were treated with 50 ng/ml tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or elevated pressure (EP) for 48 h. Protein lysates were probed for DR4, DR5, Bid, Bax, Bcl-2, X-linked inhibitor of apoptosis protein (XIAP) and GAPDH using western blot analysis. Representative blots from three independent experiments are shown; GAPDH was used as the loading control. C -The mitochondrial membrane potential (MMP) of the cells was determined using JC-1 staining. MMP is presented as the green/red ratio of JC-1 dye in the cells. *p < 0.05 (significant difference). The histogram values were expressed as the means ± standard deviation (SD) from three to five independent experiments.
The relative intensities of specific signals for DR4 were quantified using the Kodak MI system. The ratios of density values of DR4 in all treated cells to those in control cells were 1:1.25:1.22:1.10 (control group, elevated pressure group, TRAIL group, elevated pressure plus TRAIL group). These results indicate that the DR4 level in cells co-treated with elevated pressure and TRAIL does not correlate with high levels of apoptosis. The signals initiated by the TRAIL receptors can be amplified by the mitochondrial signaling pathway [18] and the Bcl-2 family of proteins regulates apoptosis by controlling mitochondrial permeability [19, 20] . We assessed the levels of the anti-apoptotic protein XIAP and the pro-apoptotic Bcl-2-associated X (Bax) protein and found that their expression did not change significantly in cells treated with either elevated pressure or TRAIL or their combination. However, elevated pressure and TRAIL co-treatment induced downregulation of the anti-apoptotic protein Bcl-2 and the BH3 interacting-domain death agonist (BID) protein ( Fig. 2A, B) . BID is a well-known key molecule that significantly amplifies apoptotic stress at the mitochondrial level [18] . Therefore, we measured the mitochondrial membrane potential (MMP) of cells in response to the treatments using JC-1 staining. As shown in Fig. 2C , the MMP was clearly higher in cells co-treated with elevated pressure and TRAIL than in cells treated with elevated pressure or TRAIL alone. Collectively, these results suggest that cotreatment with elevated pressure and TRAIL potentiates mitochondrial signaling.
Elevated pressure and TRAIL-induced reduction in phosphorylated ERK1/2, CREB and BAD
To better understand the factors contributing to elevated pressure-stimulated sensitization in TRAIL-resistant Hep3B cells, we measured the phosphorylation status of eighteen major MAPKs, most of which were well known for interfering with TRAIL resistance. Phosphorylated ERK1/2 and CREB were markedly lower in Hep3B cells exposed to elevated pressure than in control cells (Fig. 3A) . These results were verified through western blot analysis (Fig. 3B) . Fig. 3 . Co-treatment with elevated pressure and TRAIL suppresses phosphorylation of ERK, Bad and CREB. A -The phosphorylation of 18 protein kinases was analyzed using a human phospho-MAPK array kit. Significant differences in the expression of phosphorylated ERK1/2 and CREB are shown between Hep3B cells treated with elevated pressure (EP) and control cells. B -Hep3B cells were treated with elevated pressure and 50 ng/ml tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for 48 h. Total protein extracts were probed for several protein kinases using western blot analysis. Representative blots from three independent experiments are shown; GAPDH was used as the loading control.
Co-downregulation of phosphorylated ERK1/2 and CREB was observed after co-treatment with elevated pressure and TRAIL, compared with the TRAIL-only treatment. It has been reported that ERK1/2 activates p90RSK and CREB, thereby influencing the transcription of pro-survival genes including Bcl-xL and Bcl-2 [21] . Here, we found that Bcl-2 expression decreased in cells treated with an ERK1/2 inhibitor and TRAIL (Fig. 4C) , consistent with the result of co-treatment with elevated pressure and TRAIL (Fig. 2B) . Since the anti- Fig. 4 . Suppression of ERK1/2 phosphorylation enhances TRAIL-induced apoptosis. A -For inhibition of ERK1/2 phosphorylation, Hep3B cells were pre-treated with 20 μM PD98059 (Calbiochem) for 1 h before treatment with 50 ng/ml tumor necrosis factor-related apoptosisinducing ligand (TRAIL) for 48 h. Apoptosis was measured by annexin V and propidium iodide staining. B -The mitochondrial membrane potential (MMP) of Hep3B cells was determined using JC-1 staining after treatment with PD, TRAIL, or both. MMP is presented as the green to red ratio of JC-1 dye in the cells. The values of histogram were expressed as the means ± standard deviation (SD) from three to five independent experiments performed. C -After treatment of Hep3B cells with TRAIL (50 ng/ml) and ERK1/2 inhibitor (PD98059, Millipore) for 48 h, the levels of pERK, ERK, caspase-8, BID, caspase-9, caspase-3, pBAD (s112) and GAPDH were detected using western blot analysis. **p < 0.001 and *p < 0.05 (significant differences). Representative blots from three independent experiments are shown; GAPDH was used as the loading control. apoptotic downstream effects of pERK1/2 might counteract the apoptosissensitizing activity of elevated pressure, the phosphorylation status of BAD, a cytoplasmic downstream target of pERK1/2, was examined. As shown in Fig. 3B , the phosphorylation of BAD at Ser-112 decreased after treatment with elevated pressure alone and in combination with TRAIL. To confirm the critical role of elevated pressure in suppressing ERK1/2 activation, PD98059, a well-known ERK inhibitor, was used instead of elevated pressure in combination with TRAIL. As shown in Fig. 4A , co-treatment with PD98059 and TRAIL overcame the TRAIL resistance in Hep3B cells. However, inhibition of ERK phosphorylation alone was not sufficient to induce apoptosis in Hep3B cells, suggesting that the effects of TRAIL were essential to this effect. We also measured MMP to evaluate apoptotic events in the mitochondria. While exposure to PD98059 alone had no effect, co-treatment with PD98059 and TRAIL increased the MMP significantly (Fig. 4B) . Furthermore, we observed that the exposure of Hep3B cells to PD98059 and TRAIL promoted TRAIL-induced activation of caspases and downregulation of BID, Bcl-2 and pBAD (Fig. 4C) . Our results indicate that the blocking of ERK1/2 activation by co-treatment with elevated pressure and TRAIL is a critical mechanism for sensitizing cells to TRAIL-induced apoptosis with the activation of caspases, phosphorylation of CREB, downregulation of BAD, and amplification of the mitochondrial signaling pathway.
DISCUSSION
Many cancer cells exhibit resistance to the pro-apoptotic effect of TRAIL, and hepatocellular carcinomas (HCC) in particular are known for their strong resistance to TRAIL [22] . Previous studies have demonstrated that combined treatment with elevated pressure and TRAIL enhanced apoptosis in various cancer cells [8, 9] . Therefore, we chose the HCC cell line Hep3B to investigate the effect of elevated pressure on sensitivity to TRAIL and explore the underlying mechanisms. Several molecular mechanisms of TRAIL resistance have been proposed, including functional defects in TRAIL receptors such as DR4 and DR5 [23] . Thus, the upregulation of TRAIL receptors has been suggested as a mechanism to explain the TRAIL-sensitizing effect of apoptosis-enhancing compounds in HCC cells, including Hep3B [24] [25] [26] [27] [28] . We therefore studied the effect of elevated pressure on the expression of DR4 and DR5 receptors in Hep3B cells, but found no change in expression levels due to elevated pressure alone or in combination with TRAIL. Another possible explanation for TRAIL resistance is the ability of tumor cells to avoid cell death via the activation of certain survival signals [29, 30] . Among the survival signaling pathways, there have been many reports about the engagement of tyrosine kinase receptors by their ligands, including the PI3K/Akt and MAPK/ERK pathways, which play pivotal roles in preventing the induction of apoptosis [14] [15] [16] [17] . Furthermore, the inhibition of PI3K/Akt40 or MAPK/ERK increases the sensitivity of tumor cells to TRAIL-induced apoptosis [31] [32] [33] . Here, we found no changes in the levels of most phosphorylated MAP kinases, including PI3K/AKT, in Hep3B cells treated with elevated pressure. The only exceptions were ERK1/2 and CREB. Interestingly, reduced phosphorylation of ERK1/2 and CREB, along with increased apoptosis, was observed in cells treated with elevated pressure alone and in combination with TRAIL. It has been reported that ERK1/2 is over-activated in Hep3B cells [22] . These data indicate that the blocking of ERK1/2 activation is necessary to sensitize TRAIL-treated Hep3B cells by elevated pressure.
Hepatoma cells are resistant to TRAIL because of insufficient activation of the extrinsic apoptotic pathway and, more importantly, blocking of death signaling at the mitochondrial level [22, 34] . Interestingly, downregulation of pBAD as a mediator molecule for maintaining MMP was observed in Hep3B cells treated with elevated pressure and TRAIL without changing of DRs, which suggested apoptotic mechanisms caused by elevated pressure and TRAIL are associated with intrinsic not extrinsic pathways. Moreover, suppression of ERK1/2 phosphorylation by an inhibitor of ERK1/2 and TRAIL enhanced TRAILinduced apoptosis and suppression of BAD phosphorylation. Consistent with our results, it has been reported that inactivated ERK1/2 enhances TRAIL-induced apoptosis in melanoma and glioblastoma cells through the inhibition of phosphorylated BAD [35, 36] . The inactive form of BAD, phosphorylated at Ser-112 by ERK1/2, is sequestered in the cytosol bound to the 14-3-3 protein, thus freeing Bcl-XL and Bcl-2 to promote cell survival [37, 38] . These findings indicate that ERK1/2 inactivation by elevated pressure acts as a critical mechanism for sensitization of Hep3B cells to TRAIL through intrinsic pathways. A number of compounds enhance TRAIL-induced apoptosis, including cytotoxic anticancer drugs [39] , histone deacetylase inhibitors [40] , cyclin-dependent kinase inhibitors [41] , proteasome inhibitors [34] and some natural products [42] [43] [44] . However, these agents show enhancement of TRAIL-induced apoptosis with undesirable side effects to normal cells [45] . Therefore, another strategy is needed to enhance TRAIL-induced apoptosis without toxic effects to normal cells. We have previously demonstrated the TRAIL-sensitizing effects of elevated pressure in numerous cancer cells and have shown that it exhibits very low toxicity in normal fibroblasts [10] . Moreover, the combination of elevated pressure and the anticancer drug cis-diamminedichloroplatinum(II) was found to enhance the chemo-sensitivity of lung cancer cells [8, 9] . There have been few reports regarding the combined effect of chemotherapeutic drugs and mechanical stress in the potentiation of cancer cell apoptosis. Here, we have confirmed the TRAIL-sensitizing effects of elevated pressure as a mechanical stressor in TRAIL-resistant Hep3B cells following previous studies for several cancer cells including lung carcinoma, human glioblastoma, human epithelial cervical carcinoma and acute T-cell leukemia. These apoptosis-potentiating activities have several possible molecular mechanisms, including the suppression of elevated pressure-mediated ERK1/2 activation and amplification of the intrinsic apoptotic pathway. Therefore, elucidation of the mechanism by which elevated pressure mediates ERK inactivation is critical for the development of new strategies to induce apoptosis in drug-resistant cancer cells and minimize cytotoxic effects on normal cells. a future environmental R&D grant (RE201206020) funded by the Korean Environmental Industry and Technology Institute.
